| Market Cap | 1.27B | P/E | - | EPS this Y | 93.50% | Ern Qtrly Grth | - |
| Income | -88.09M | Forward P/E | -11.49 | EPS next Y | -20.50% | 50D Avg Chg | 14.00% |
| Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | 16.00% |
| Dividend | N/A | Price/Book | 2.45 | EPS next 5Y | - | 52W High Chg | -33.00% |
| Recommedations | 2.20 | Quick Ratio | 51.32 | Shares Outstanding | 43.76M | 52W Low Chg | 176.00% |
| Insider Own | 12.00% | ROA | -15.25% | Shares Float | 17.91M | Beta | - |
| Inst Own | 94.12% | ROE | -26.91% | Shares Shorted/Prior | 338.64K/2.17M | Price | 29.06 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 630,765 | Target Price | 41.00 |
| Oper. Margin | - | Earnings Date | Nov 3 | Volume | Change | 0.00% |
CinCor Pharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of drugs for the treatment for cardio-renal diseases. It is involved in developing CIN-107, which is in Phase II clinical trial for the treatment of hypertension, primary aldosteronism, and other cardio-renal diseases, as well as in Phase I clinical trial to treat chronic kidney diseases. The company was incorporated in 2018 and is based in Waltham, Massachusetts. As of February 23, 2023, CinCor Pharma, Inc. operates as a subsidiary of AstraZeneca Finance and Holdings Inc..
| Barclays | Equal-Weight | Jan 12, 23 |
| Morgan Stanley | Equal-Weight | Jan 10, 23 |
| Barclays | Overweight | Dec 8, 22 |
| Barclays | Overweight | Dec 7, 22 |
| Morgan Stanley | Equal-Weight | Nov 29, 22 |
| Oppenheimer | Perform | Nov 29, 22 |
| Goldman Sachs | Buy | Oct 28, 22 |
| Morgan Stanley | Overweight | Sep 9, 22 |
| Piper Sandler | Overweight | Aug 22, 22 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| HEALY JAMES | Director Director | Nov 28 | Sell | 14.32 | 6,000 | 85,920 | 02/27/23 | |
| 5AM Partners VI, LLC | 10% Owner 10% Owner | Aug 15 | Buy | 30 | 600,000 | 18,000,000 | 487,333 | 08/17/22 |
| Sofinnova Partners SAS | 10% Owner 10% Owner | Aug 15 | Buy | 30.00 | 133,333 | 3,999,990 | 4,220,979 | 08/17/22 |
| Sofinnova Venture Partners X,... | 10% Owner 10% Owner | Aug 11 | Buy | 30 | 500,000 | 15,000,000 | 6,073,949 | 08/15/22 |
| HEALY JAMES | Director Director | Aug 11 | Buy | 30 | 506,000 | 15,180,000 | 6,000 | 08/15/22 |
| GENERAL ATLANTIC GENPAR (BERMU... | 10% Owner 10% Owner | Aug 11 | Buy | 30.00 | 83,000 | 2,490,000 | 4,209,470 | 08/15/22 |
| GENERAL ATLANTIC, L.P. | 10% Owner 10% Owner | Aug 11 | Buy | 30.00 | 83,000 | 2,490,000 | 4,209,470 | 08/15/22 |
| HEALY JAMES | Director Director | Aug 05 | Option | 13.60 | 29,411 | 399,990 | 29,411 | 08/08/22 |
| GENERAL ATLANTIC GENPAR (BERMU... | 10% Owner 10% Owner | Jan 11 | Buy | 16 | 1,700,000 | 27,200,000 | 4,126,470 | 01/13/22 |
| GENERAL ATLANTIC, L.P. | 10% Owner 10% Owner | Jan 11 | Buy | 16 | 1,700,000 | 27,200,000 | 4,126,470 | 01/13/22 |
| 5AM Partners VI, LLC | 10% Owner 10% Owner | Jan 11 | Buy | 16 | 470,000 | 7,520,000 | 496,323 | 01/13/22 |